DAV, Americans for Ibogaine Launch Partnership to Advance Veteran Research and Policy Advocacy

ERLANGER, Ky.—DAV (Disabled American Veterans) and Americans for Ibogaine today announced a partnership aimed at advancing education, awareness, research and advocacy surrounding emerging psychedelic therapies for veterans.

This collaboration brings together DAV’s century-long mission of advocacy and support for veterans with Americans for Ibogaine’s focus on policy reform and expanding safe, evidence-based access related to Ibogaine research and treatment.

“Veterans are seeking new solutions to complex health challenges, particularly in areas related to brain injuries, PTSD and substance use disorder” said DAV CEO Barry Jesinoski. “This partnership is about ensuring they have access to credible information, ongoing research and a thoughtful veteran-focused conversation about emerging therapies.”

Ibogaine, a naturally occurring psychoactive compound, has drawn increasing attention for its potentially transformative role in treating addiction and trauma-related conditions. While ibogaine is not currently approved for medical use at the federal level, research initiatives and policy discussions have advanced at the state level.

“Americans For Ibogaine is focused on expediting the medicalization of psychedelics in the U.S. with an emphasis on ibogaine as a potential breakthrough treatment for trauma and addiction, said Americans for Ibogaine CEO Bryan Hubbard. “Veterans have been forced to leave the country they have served in order to access ibogaine treatment when all other options have failed. We are proud to partner with DAV to ensure progress for a movement which began with veterans which now seeks to serve all of humanity.”

Continue reading the full article →

Source: DAV News
Website: www.dav.org